Scottish HTA Body OKs Vyxeos & Prevymis, But Rejects Kymriah In Lymphoma
Executive Summary
The Scottish Medicines Consortium has OKd the use of two orphan drugs, Vyxeos for AML and Prevymis for preventing CMV reactivation, but rejected Novartis’s CAR-T therapy Kymriah, for use in lymphoma.
You may also be interested in...
Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
UK: Funding For Second Kymriah Indication After Talks And Price Cut
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.